Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027

Loading news article.

Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027 | WAPE

Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027

Article summary

Related companies

Comments —